The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: A placebo-controlled, 24-month randomized study

Metabolism: Clinical and Experimental

Volumn 52, Issue 9, 2003, Pages 1211-1217

  Schuster, Dara ^a   Gaillard, T ^a   Rhinesmith, S ^a   Habash, D ^a   Osei, K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; C PEPTIDE; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; LIPID; LIPOPROTEIN; PLACEBO; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AGE; ANAMNESIS; ANTHROPOMETRIC PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BODY MASS; BODY WEIGHT; CARDIOVASCULAR PARAMETERS; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET; DOUBLE BLIND PROCEDURE; DRUG DISPOSITION; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; FAMILIAL INCIDENCE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT MONITORING; POPULATION RESEARCH; POPULATION RISK; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0141758540     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00160-4     Document Type: Article

References (46)

1. Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21:518-524, 1998
2. Svec F, Nastasi K, Hilton C, et al.: Black-white contrast in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes 41:313-317, 1992
3. Arslanian S, Suprasongsin C: Black/white differences in vivo insulin secretion and sensitivity in childhood. Diabetes 44:196A, 1995 (suppl 1)
4. Osei K, Schuster DP: Ethnic differences in secretion, sensitivity, and hepatic extraction of insulin in black and white Americans. Diabet Med 11:155-762, 1994
5. Porte D Jr. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Rev 17:181-188, 2001
6. Stumvoll M, Gerich J: Clinical features of insulin resistance and β cell dysfunction and the relationship to type 2 diabetes. Clin Lab Med 21:31-51, 2001
7. Karter AJ, Mayer-Davis EJ, Selby JV, et al.: Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes 45:1547-1555, 1996
8. Haffner SM: Epidemiology of type 2 diabetes: Risk factors. Diabetes Care 21:C3-6, 1998 (suppl 3)
9. Mayer-Davis EJ, Levin S, Bergman RN, et al.: Insulin secretion, obesity, and potential behavioral influences: Results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Metab Rev 17:137-145, 2001
10. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
11. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al.: Early metabolic defects in persons at increased risk for noninsulin-dependent diabetes mellitus. N Engl J Med 321:337-343, 1989
12. Osei K, Gaillard T, Schuster DP: Pathogenetic mechanisms of impaired glucose tolerance and type 2 diabetes in AA: The significance of insulin secretion, insulin sensitivity and glucose effectiveness. Diabetes Care 20:745-752, 1997
13. Frisch RE, Wyshak G, Albright TE, et al.: Lower prevalence of diabetes in female former college athletes compared with nonathletes. Diabetes 35:1101-1105, 1986
14. O'Dea K, Patel M, Kubisch D, et al.: Obesity, diabetes, and hyperlipidemia in a central Australian aboriginal community with a long history of acculturation. Diabetes Care 16:1004-1010, 1993
15. Teuscher T, Baillod P, Rosman JB, et al.: Absence of diabetes in a rural West African population with a high carbohydrate/cassava diet. Lancet 1:765-768, 1987
16. Salmeron J, Hu FB, Manson JE, et al.: Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 73:1019-1026, 2001
17. Hu FB, Willett WC J: Diet and coronary heart disease: Findings from the Nurses' Health Study and Health Professionals' follow-up Study. Nutr Health Aging 5:132-138, 2001
18. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 34:891-898, 1991
19. Pan XR, Li GW, Hu YH, et al.: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
20. Eriksson J, Lindstrom J, Valle T, et al.: Prevention of type II diabetes in subjects with impaired glucose tolerance: The Diabetes Prevention Study (DPS) in Finland: Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 42:793-801, 1999
21. The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-401, 2002
22. Sartor G, Schersten B, Carlstrom S, et al.: Ten-year follow-up of subjects with impaired glucose tolerance: Prevention of diabetes by tolbutamide and diet regulation. Diabetes 29:41-49, 1980
23. Fonseca VA, Valiquett TR, Huang SM, et al.: Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study. J Clin Endocrinol Metab 83:3169-3176, 1998
24. Nolan JJ, Ludvik B, Beerdsen P, et al.: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Eng J Med 331:1188-1193, 1994
25. Ehrmann DA, Schneider DJ, Sobel BE, et al.: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108-2116, 1997
26. Dunaif A, Scott D, Finegood D, et al.: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299-3306, 1996
27. Mimura K, Umeda F, Hiramatsu S, et al.: Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685-691, 1994
28. Buchanan TA: Pancreatic B-cell defects in gestational diabetes: Implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86;989-993, 2001
29. Baumgartner RN, Chumela WC, Roches AF: Estimation of body composition from bioelectric impedance of body segments. Am J Clin Nutr 30:221-226, 1989
30. Lukaski HC, Bolonchuk WW, Hall CV, et al.: Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol 60:1327-1332, 1986
31. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
32. World Health Organization (WHO): Diabetes Mellitus. Report of a WHO study group. Tech Rep ser 727, Geneva, Switzerland, 1985, pp 7-25
33. Hong Y, Weisnagel SJ, Rice T, et al.: Familial resemblance for glucose and insulin metabolism indices derived from an intravenous glucose tolerance test in Blacks and Whites of the HERITAGE Family Study. Clin Genet 60:22-30, 2001
34. Faber OK, Madsbad S, Kehlet H, et al.: Pancreatic β-cell secretion during oral and intravenous glucose administration. Acta Med Scand 624:61-64, 1979 (suppl)
35. Bergman RN, Prager R, Volund A, et al.: Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79:790-800, 1987
36. Carter HS, Pugh JA, Monterossa A: Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 125:221-232, 1996
37. Pugh JA, Medina RA, Cornell JC, et al.: NIDDM is the major cause of diabetic end-stage renal disease. More evidence from a tri-ethnic community. Diabetes 44:1375-1380, 1995
38. Brancati FL, Whittle JC, Whelton PK, et al.: The excess incidence of diabetic end-stage renal disease among blacks. JAMA 268:3079-3084, 1992
39. Prigeon RL, Kahn SE, Porte D Jr.: Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:819-823, 1998
40. Kemnitz JW, Elson DF, Roecker EB, et al.: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 43:204-211, 1994
41. Tack CJ, Smits P, Demacker PN, et al.: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21:796-799, 1998
42. Scheen AJ: Thiazolidinediones and liver toxicity. Diabetes Metab 27:305-313, 2001
43. Gorson DM: Significant weight gain with rezulin therapy. Arch Intern Med 159:99, 1999
44. King AB: A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 233:557, 2000
45. Buckingham RE, Al-Barazanji KA, Toseland CD, et al.: Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326-1334, 1998
46. Buchanan TA, Ziang AH, Peters RK, et al.: Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002